Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ ...

Stifel reiterated a Buy rating and $230 price target on Jazz Pharmaceuticals (JAZZ) after the company agreed to acquire Chimerix (CMRX). The ...

Jazz Pharmaceuticals said Wednesday it would spend nearly $1 billion to buy Chimerix and its experimental pill for a ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an ...